Advances in targeted therapy for triple-negative breast cancer
10.3969/j.issn.1000-8179.2019.12.479
- VernacularTitle:三阴性乳腺癌靶向治疗进展
- Author:
Guolei DONG
1
;
Weipeng ZHAO
;
Zhongsheng TONG
Author Information
1. 天津医科大学肿瘤医院乳腺肿瘤内科
- Keywords:
triple-negative breast cancer;
targeted therapy;
poly ADP-ribose polymerase (PARP);
Trop-2;
immune checkpoints;
andro-gen;
anti-angiogenic
- From:
Chinese Journal of Clinical Oncology
2019;46(12):649-652
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that is characterized by the lack of estro-gen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2), thereby making it difficult to treat. Owing to the aggressive clinical behavior of TNBC and the lack of recognized molecular targets for therapy, patients with TNBC have shown poorer outcomes than those with other subtypes of breast cancer. Chemotherapy is the primary established systemic treatment for TNBC. However, various novel therapeutic targets have come into focus with the advances in molecular characterization of TNBC. In recent years, several targeted drugs have undergone clinical trials and have shown certain curative effects with relatively mild adverse reactions. The Food and Drug Administration has approved some of these drugs. In the current review, we have summa-rized the advances in the targeted therapy of TNBC.
